Soleno Therapeutics, Inc.
SLNO
$33.39
-$0.37-1.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.41M | 98.68M | 32.66M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.41M | 98.68M | 32.66M | -- | -- |
| Cost of Revenue | 2.70M | 1.84M | 696.00K | -- | -- |
| Gross Profit | 187.71M | 96.84M | 31.96M | -- | -- |
| SG&A Expenses | 132.13M | 128.55M | 144.00M | 126.65M | 105.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.46M | 182.95M | 218.98M | 204.13M | 184.43M |
| Operating Income | 14.95M | -84.27M | -186.32M | -204.13M | -184.43M |
| Income Before Tax | 20.89M | -78.45M | -181.08M | -198.23M | -175.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.89 | -78.45 | -181.08 | -198.23 | -175.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.89M | -78.45M | -181.08M | -198.23M | -175.85M |
| EBIT | 14.95M | -84.27M | -186.32M | -204.13M | -184.43M |
| EBITDA | 16.97M | -82.26M | -184.32M | -202.13M | -182.44M |
| EPS Basic | 0.25 | -1.83 | -4.15 | -4.62 | -4.26 |
| Normalized Basic EPS | 0.23 | -1.08 | -2.52 | -2.80 | -2.61 |
| EPS Diluted | 0.22 | -1.85 | -4.15 | -4.62 | -4.26 |
| Normalized Diluted EPS | 0.21 | -1.09 | -2.52 | -2.80 | -2.61 |
| Average Basic Shares Outstanding | 203.17M | 193.92M | 182.47M | 170.61M | 160.64M |
| Average Diluted Shares Outstanding | 205.92M | 195.51M | 182.47M | 170.61M | 160.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |